Afficher la notice abrégée

Metronomic Reloaded: Theoretical Models Bringing Chemotherapy into the Era of Precision Medicine

hal.structure.identifierModélisation Mathématique pour l'Oncologie [MONC]
hal.structure.identifierInstitut de Mathématiques de Bordeaux [IMB]
dc.contributor.authorBENZEKRY, Sébastien
hal.structure.identifierMetronomics Global Health Initiative
hal.structure.identifierChildren's Cancer Institute
hal.structure.identifierCentre de Recherches en Oncologie biologique et Oncopharmacologie [CRO2]
dc.contributor.authorPASQUIER, Eddy
hal.structure.identifierCentre de Recherches en Oncologie biologique et Oncopharmacologie [CRO2]
dc.contributor.authorBARBOLOSI, Dominique
hal.structure.identifierHôpital de la Timone [CHU - APHM] [TIMONE]
dc.contributor.authorLACARELLE, Bruno
hal.structure.identifierHôpital Nord [CHU - APHM]
dc.contributor.authorBARLÉSI, Fabrice
hal.structure.identifierMetronomics Global Health Initiative
hal.structure.identifierCentre de Recherches en Oncologie biologique et Oncopharmacologie [CRO2]
hal.structure.identifierHôpital de la Timone [CHU - APHM] [TIMONE]
dc.contributor.authorANDRÉ, Nicolas
hal.structure.identifierCentre de Recherches en Oncologie biologique et Oncopharmacologie [CRO2]
hal.structure.identifierHôpital de la Timone [CHU - APHM] [TIMONE]
dc.contributor.authorCICCOLINI, Joseph
dc.date.accessioned2024-04-04T03:17:42Z
dc.date.available2024-04-04T03:17:42Z
dc.date.created2015
dc.date.issued2015
dc.identifier.issn1044-579X
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/194329
dc.description.abstractEnOncology has benefited from an increasingly growing number of groundbreaking innovations over the last decade. Targeted therapies, biotherapies, and the most recent immunotherapies all contribute to increase the number of therapeutic options for cancer patients. Consequently, substantial improvements in clinical outcomes for some disease with dismal prognosis such as lung carcinoma or melanoma have been achieved. Of note, the latest innovations in targeted therapies or biotherapies do not preclude the use of standard cytotoxic agents, mostly used in combination. Importantly, and despite the rise of bioguided (a.k.a. precision) medicine, the administration of chemotherapeutic agents still relies on the maximum tolerated drug (MTD) paradigm, a concept inherited from theories conceptualized nearly half a century ago. Alternative dosing schedules such as metronomic regimens, based upon the repeated and regular administration of low doses of chemotherapeutic drugs, have emerged as possible strategies to improve response rates while reducing toxicities. The recent changes in paradigm in the way we theorize cancer biology and evolution, metastatic spreading and tumor ecology, alongside the recent advances in the field of immunotherapy, have considerably strengthened the interest for metronomic approaches. This paper aims at reviewing the recent evolutions in the field of theoretical biology of cancer and computational oncology, with a focus on the consequences these changes have on the way we administer chemotherapy. In particular, a step towards developing adaptive dosing should help to further optimize the efficacy of metronomic therapy. There is a rising trend to establish personalized medicine in oncology. Developing extensive bio-guided strategies for decision-making in the choice of drugs to be administered is now a common practice at the bedside. Similarly, developing extensive model-guided strategies for decision-making in refining dosing and scheduling should be undertaken to achieve precision medicine in oncology.
dc.language.isoen
dc.publisherElsevier
dc.subject.enMetronomic chemotherapy
dc.subject.enmathematical modeling
dc.subject.enPK/PD
dc.subject.enprecision medicine 2
dc.title.enMetronomic Reloaded: Theoretical Models Bringing Chemotherapy into the Era of Precision Medicine
dc.typeArticle de revue
dc.identifier.doi10.1016/j.semcancer.2015.09.002
dc.subject.halSciences du Vivant [q-bio]/Cancer
bordeaux.journalSeminars in Cancer Biology
bordeaux.page23
bordeaux.hal.laboratoriesInstitut de Mathématiques de Bordeaux (IMB) - UMR 5251*
bordeaux.institutionUniversité de Bordeaux
bordeaux.institutionBordeaux INP
bordeaux.institutionCNRS
bordeaux.peerReviewedoui
hal.identifierhal-01195547
hal.version1
hal.popularnon
hal.audienceInternationale
hal.origin.linkhttps://hal.archives-ouvertes.fr//hal-01195547v1
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Seminars%20in%20Cancer%20Biology&rft.date=2015&rft.spage=23&rft.epage=23&rft.eissn=1044-579X&rft.issn=1044-579X&rft.au=BENZEKRY,%20S%C3%A9bastien&PASQUIER,%20Eddy&BARBOLOSI,%20Dominique&LACARELLE,%20Bruno&BARL%C3%89SI,%20Fabrice&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée